Notice

Life Sciences Innovative Manufacturing Fund (LSIMF): ExpressionPhase of2 Interest(closed to applications)

TheThis Lifefund Sciencesis Innovativeto Manufacturingsupport Fund supports businesses investing in life sciences manufacturing projects in the UK.

From:
Department for Science, Innovation and Technology and Office for Life Sciences
Published
2 March 2022
Last updated
3126 OctoberFebruary 2024 — See all updates

Documents

Life Sciences Innovative Manufacturing FundFund: (LSIMF):scheme applicationguidance guide(updated 2 May 2023)

HTMLPDF, 324 KB, 13 pages

Grant offer letter: draft template

PDF, 320 KB, 15 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alt.formats@dsit.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Life Sciences Innovative Manufacturing FundFund: (LSIMF): privacy notice

HTML

Details

31The OctoberLife 2024:Sciences updateInnovative Manufacturing Fund (LSIMF) Phase 2 is now closed to new applications.

Background and objectives of the programme

The Life Sciences Innovative Manufacturing Fund (LSIMF) is openpart of the Global Britain Investment Fund and will acceptprovide Expression£60 million in capital grants for investment in the manufacture of:

  • human medicines (drug substance and drug product)
  • medical diagnostics
  • MedTech products

We have already announced the first tranche of Interestscompanies (EOIto be supported by LSIMF) onand aare rollingnow basis.re-opening the fund with the remaining budget of £7.6 million.

Specific themes

TheWe government’sparticularly planwelcome forapplications Lifefrom Sciencescompanies –with ‘Amanufacturing Prescriptioninvestments forthat Growth’demonstrate committedthe upadoption toof £520innovative millionprocess technologies, for lifeexample:

  • flexible sciencesmanufacturing enabling manufacturing,rapid toproduct helpswitching
  • continuous delivermanufacturing
  • technologies that will minimise impact of the product or the manufacturing process on the government’senvironment
  • digital missionstwins, towhich kickstartharness economicthe growthpower of data analytics and buildmodelling anto NHSoptimise fitmanufacturing forprocesses

This list is not exhaustive.

Fund objectives

We will prioritise applicants based on their alignment to the future.fund’s objectives:

The1. Creating LSIMFeconomic opportunity through investments that will beprovide UKhigh-wage, andhigh-skilled sectorjobs.

2. Deploying widecutting-edge innovations (at both pilot and willcommercial providescale) capitalwhich grantscan forbe investmentsembedded in either the manufactureproduct of:itself or the manufacturing process.

  • Human

    3. Increasing medicineshealth (thisresilience, includeseither boththrough theincreased manufacturedomestic ofcapacity activeor pharmaceuticalby ingredientsproviding (API)flexible /capabilities drugthat substancecan andbe finishedre-deployed productin /some drugway product).

  • Medicalin diagnosticsa –future forhealth bothemergency.

    4. Minimising diseaseimpact identificationon andthe monitoring.

  • MedTechenvironment, productswhich –might allinclude typesreduction ofin medicalinput devicesresources relatedor using alternative input materials to humanbecome health.

Thismore guidancesustainable includesor informationsupport aboutthe government’s net zero target.

Contact

Contact the LSIMF andsupport team if you have any queries about the applicationfund: process.LSIMF@officeforlifesciences.gov.uk.

Updates to this page

Published 2 March 2022
Last updated 3126 OctoberFebruary 2024 + show all updates

  1. The Life Sciences Innovative Manufacturing Fund (LSIMF) is open and will accept Expression of Interests (EOI) on a rolling basis.

  2. Life Sciences Innovative Manufacturing Fund (LSIMF): Phase 2 closed to applications.

  3. Phase 2 open to Expressions of Interest.

  4. Phase 1 is now closed to Expressions of Interest.

  5. Submit expressions of interest for Phase 1, Wave 3 by 31 May 2022, 12 noon.

  6. Wave 2 expressions of interest date added.

  7. Date for submitting expressions of interest to the LSIMF Phase 1 Wave 1 changed to Friday 29 April at 12 noon.

  8. First published.

Sign up for emails or print this page